Filtered By:
Drug: Tamiflu
This page shows you your search results in order of date.
Order by Relevance | Date
Total 11 results found since Jan 2013.
Current status of drug repositioning in hematology
Expert Rev Hematol. 2021 Oct 16. doi: 10.1080/17474086.2021.1995348. Online ahead of print.ABSTRACTINTRODUCTION: Drug repositioning (DR) is defined as determining new therapeutic applications for existing drugs. This approach is advantageous over de novo drug discovery in accelerating clinical development, in terms of lower costs, a shortened development period, a well-known action mechanism, a feasible dosage, and an acceptable safety profile.AREAS COVERED: This work was aimed at reviewing agents with successful DR in hematology.EXPERT OPINION: Thalidomide and plerixafor have been successfully repositioned for treating mu...
Source: Expert Review of Hematology - October 18, 2021 Category: Hematology Authors: Akihiro Ohmoto Shigeo Fuji Source Type: research
Lack of trial data may lead to wrong clinical choices
Data access should be mandatory, argue authorsRelated items from OnMedicaDoctors’ leaders consult on ethical use of dataDrug giant agrees to release all Tamiflu trial dataNICE rejects arguments against wider statin useUS doctor says FDA should have withdrawn rosuvastatinTime to rethink 4.5h window for alteplase after stroke
Source: OnMedica Latest News - October 23, 2015 Category: UK Health Source Type: news
